The inhibition of the β-catenin mediated pathway, whichpromotes the development of colon cancer and is stimulated by COX-2 as well as PGE2 [69, 70], by nonsteroidal anti-inflammatory drugs,requires a high-level expression of RXRαand PPARγ[71].Therefore, the activation of the RXR/PPARγ heterodimer by the coadministration of their ligands isclinically useful for the preventionand/or treatment of colon cancer as well as colonic inflammation [72], due to theirsynergistic effects on the COX-2/PGE2 axis. The gene discussed is PTGS2; the disease is colitis.